[ad_1]
Chaska, Minn., March 26, 2024 (Globe Newswire) — Lifecore Biomedical, Inc. (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (“CDMO”) (“Lifecore” or ” The Company today announced that Ernst & Young LLP, the Company’s independent registered public accounting firm for the year ended May 28, 2023, was the Company’s independent registered public accounting firm for the year ended May 26, 2023. announced that he has decided to decline his candidacy for re-election. 2024 following the filing of the Company’s Annual Report on Form 10-K. Lifecore’s board of directors has begun a search for a replacement.
In addition, the Company plans to provide a business update on Monday, April 1, 2024, which will include certain selected financial data and commercial business updates for fiscal year 2024.
About Lifecore Biomedical
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) that provides highly differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. is. Lifecore, a leading manufacturer of premium injectable-grade hyaluronic acid, brings over 40 years of expertise and brings innovation to market as a partner to global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories. I’m putting it in. For more information about our company, please visit Lifecore’s website at www.lifecore.com.
Important note regarding forward-looking statements
This press release contains certain forward-looking statements that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. and contains forward-looking statements regarding our future results. “anticipate”, “estimate”, “expect”, “plan”, “project”, “intend”, “believe”, “may”, “might”, “will” Words such as “,” “should,” “could,” “likely,” and similar expressions are used to identify forward-looking statements. All forward-looking statements include our evaluation of strategic alternatives and related discussions with potential bidders, our capabilities, and other factors that could cause actual results to differ materially. involve certain risks and uncertainties that may result in The filing and timing of our filings with the Securities and Exchange Commission (the “SEC”), our ability to regain compliance with Nasdaq’s applicable listing standards, and our ability to expand our relationships with existing customers will be updated. For additional information regarding factors that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors contained in our most recent Annual Report on Form 10-K. , see our SEC filings. Forward-looking statements represent management’s current expectations and are inherently uncertain. Except as required by law, we undertake no obligation to update any forward-looking statements we make to reflect subsequent events or circumstances.
Lifecore Biomedical, Inc. Contact Information:
Jeff Sonek
(646) 277-1263
jeff.sonnek@icrinc.com
[ad_2]
Source link
